Background
==========

In patients with rheumatoid arthritis (RA), inflammation, dysregulated Epstein--Barr virus (EBV) infection and immunosuppressive therapy may contribute to increased risk for developing lymphoma. We have shown that EBV load in peripheral blood mononuclear cells (PBLs) is 10-fold higher in RA patients (16 copies/500 ng DNA) than in normal controls (1.9 copies/500 ng DNA). EBV load in RA patients is similar to that in healthy transplant recipients and much lower than in symptomatic EBV-infected transplant recipients with lymphoproliferative disease (\> 500 copies/500 ng DNA).

Objectives
==========

We monitored EBV load in RA patients\' PBLs to evaluate how it was influenced by methotrexate and infliximab, and to detect lymphoma development.

Methods
=======

A total of 221 patients fulfilling the 1987 ACR criteria for RA and 100 healthy controls were studied. Of these 221 patients, 88 were followed for 1--4 years: 19 received only methotrexate (eight were included in the study before introduction of methotrexate), eight received only infliximab, and 61 received both methotrexate and infliximab. A 214 base-pair fragment from the EBV genome first internal repeat (IR1) was amplified by quantitative real-time PCR to evaluate EBV DNA load.

Results
=======

EBV load decreased dramatically in most patients right after introduction of methotrexate and kept decreasing thereafter. In patients receiving infliximab and methotrexate, three patterns of EBV load evolution were observed: stable, decreasing and variable. Patients with only infliximab had either stable or decreasing EBV loads. Although an increase in EBV load was observed in a few patients, none of them reached the 500 copies/500 ng level and no patient developed lymphoma.

Conclusions
===========

Methotrexate and infliximab do not seem to increase EBV load in patients with RA.

Acknowledgements
================

Supported by PHRC 2003 and SFR.
